Schizophrenia is one of the most challenging mental illnesses to live with and treat. Despite extensive research, no single cause of schizophrenia has been identified. Learn about the latest developments in schizophrenia medication and understand the challenges of living with schizophrenia.
The search for effective schizophrenia medications has been slow and arduous. Although more than 130 schizophrenia medications are now available since the development of the first-generation medications in 1952, only about 20 percent of individuals experience significant improvement in managing their symptoms.* Medication often needs to be coupled with daily living support, and the majority of patients continue to experience some degree of social and occupational difficulty.
The majority of schizophrenia medications are antipsychotic medications targeting the dopamine D2 receptors. This approach stems from the dopamine hypothesis of schizophrenia, which posits that dysregulation of dopamine pathways in the brain plays a critical role in the development of psychotic symptoms.
While dopamine D2 receptor antagonists are a cornerstone in the treatment of schizophrenia, a major issue with these medications is that dopamine is needed across multiple parts of the brain, not just those linked to psychosis.
Consequently, their use often results in various side effects and has limited efficacy for certain symptom domains. There are also challenges with medication adherence, which further highlights the need for the development of new schizophrenia medication options.
Researchers at a Boston-based biotech firm believe they have developed a new class of schizophrenia medication that can manage both positive and negative symptoms of schizophrenia without the common side effects associated with dopamine receptor blockers.*
This new schizophrenia medication has shown promising results in clinical trials and is currently undergoing the FDA approval process. Some researchers believe this development brings new hope for psychiatric drugs, one of the most challenging arenas in drug discovery.
Learn more about schizophrenia and the latest medical developments:
What is Schizophrenia and How Many People Live with Schizophrenia?
Schizophrenia is a long-term mental health condition. It causes a range of psychological symptoms, including disruptions in thought processes, perceptions, emotional responsiveness, and social interactions.
Schizophrenia is often described as a type of psychosis, which means the person may not always be able to distinguish their own thoughts and ideas from reality. The condition can be persistent, severe, and is frequently associated with significant impairment in various aspects of life, including personal, family, social, educational, and occupational domains.
People with schizophrenia are two to three times more likely to die early compared to the general population, often due to physical illnesses such as cardiovascular, metabolic, and infectious diseases.*
Globally, schizophrenia affects approximately 24 million people, or 0.32% of the population.* Despite the high prevalence and impact of schizophrenia, the majority of people with this condition around the world do not receive adequate mental health care due to stigma and lack of resources for mental health services and special care.
Approximately 50% of individuals in mental hospitals are diagnosed with schizophrenia, yet only about 30% of people with psychosis receive specialist mental health care. Most resources for mental health services often fail to provide the necessary support and may violate the basic human rights of patients.*
Schizophrenia patients are often over-represented among the non-married, childless, unemployed, and those with low academic achievement. They are also more likely to experience homelessness, extensive hospitalisation, incarceration, disability support reliance, supervised living arrangements, dependence on family, social isolation, poor health, victimisation, and early death.*
The WHO’s Comprehensive Mental Health Action Plan 2013-2030 outlines steps to provide appropriate services for people with mental disorders, including schizophrenia. The aim is to shift services from institutions to community-based care and ensure that 100 million more people have access to quality and affordable mental health care.
7 Facts About Schizophrenia
1. Schizophrenia Symptoms:
Schizophrenia is characterised by a range of symptoms that can include delusions, hallucinations, disorganised thinking and speech, abnormal motor behaviour, and symptoms such as diminished emotional expression. Additionally, cognitive symptoms such as issues with attention, memory, and executive functions (including planning and decision-making) are commonly observed.
2. What are the “Positive Symptoms of Schizophrenia”?
Positive symptoms of schizophrenia are referred to hallucinations (hearing or seeing things that are not there), delusions (false beliefs, often of persecution or grandeur), thought disorders (unusual or dysfunctional ways of thinking), and movement disorders (agitated body movements or catatonia).
What are the “Negative Symptoms of Schizophrenia”?
Negative symptoms of schizophrenia are referred to reduced ability to experience pleasure (anhedonia), lack of motivation (avolition), reduced speech output (alogia), diminished emotional expression, and social withdrawal.
Is Schizophrenia Genetic?
Research shows that a combination of genetics and environment can trigger the onset of schizophrenia. Having a first-degree relative with schizophrenia can increase the risk of developing the disorder. Studies suggest that multiple genes contribute to the risk, but no single gene has been found to cause the disorder on its own.
How is Schizophrenia Diagnosed?
Schizophrenia is diagnosed based on a clinical assessment, which includes a detailed history of symptoms, psychiatric evaluation, and ruling out other medical conditions. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-10) provide criteria for diagnosis.
How Does Schizophrenia Develop?
Schizophrenia typically develops in late the teens to early thirties. The exact cause is unknown, but it is believed to result from a combination of genetic, brain chemistry, and environmental factors. Early signs can include subtle changes in cognition and social relationships, and it often progresses to more severe symptoms over time.
Can Schizophrenia Be Cured?
There is currently no cure for schizophrenia. However, it can be managed with a combination of antipsychotic medications, psychosocial treatments, and supportive services. Early intervention and continuous treatment can help individuals lead productive lives.
Why Is Schizophrenia So Difficult to Treat?
Schizophrenia is a challenging disorder to treat for several reasons. One major difficulty lies in the limited understanding of the underlying mechanisms of the disorder. Despite extensive research, the complexity of schizophrenia means that the exact causes remain elusive, complicating efforts to develop targeted schizophrenia treatments.
Clinical trials are particularly difficult because animal models do not accurately replicate the human condition, making it challenging to test new therapies in a way that translates effectively to real-world scenarios. This gap in understanding significantly hampers the development of new and effective treatments.
Many patients with schizophrenia do not seek or adhere to treatment, which complicates the management of the disorder. This reluctance can stem from a variety of factors, including a lack of insight into their condition, known as anosognosia. Patients may be unaware they have an illness, leading them to refuse treatment.
Delusions and hallucinations, common symptoms of schizophrenia, can cause patients to believe that medications are harmful or that people trying to help them are threats. This fear and mistrust significantly hinder treatment adherence. Without consistent treatment, patients are more likely to experience relapses and deteriorating mental health, making it harder to achieve long-term stability.
Another challenge is the reliance on old drug paradigms that have not significantly evolved over the decades. Many current antipsychotic medications were developed based on theories and knowledge that have not kept pace with newer scientific discoveries. These drugs often come with severe side effects and limited efficacy, particularly for negative and cognitive symptoms.
Conducting successful clinical trials is difficult due to high dropout rates, placebo effects, and the heterogeneity of the patient population. These issues create substantial barriers to bringing new, effective treatments to market, leaving many patients without adequate options for managing their condition.
Current Developments in Schizophrenia Medication
The new schizophrenia medication awaiting FDA approval has generated both optimism and scepticism in the medical community. This drug represents a novel approach by combining two compounds that target muscarinic acetylcholine receptors in the brain, rather than the traditional dopamine receptors.*
This new mechanism is believed to address both positive and negative symptoms of schizophrenia more effectively and with fewer side effects than existing treatments. Clinical trials have shown significant improvements in symptom reduction compared to placebo, with benefits observed early in the treatment and increasing over time.
The new drug has demonstrated a favourable safety profile, with common side effects being mild to moderate gastrointestinal issues, and notably lacking the severe side effects such as weight gain, sedation, and movement disorders often seen with current antipsychotic drugs.
According to some researchers, the trials did not provide comprehensive data on the drug’s effects on cognitive symptoms, leaving a gap in understanding its full therapeutic profile.* Although generally well-tolerated, the long-term impact of gastrointestinal side effects and their potential to affect patient adherence remains a concern.
Transitioning from controlled clinical trial settings to real-world applications may reveal new challenges. The efficacy and safety observed in trials may not fully translate to a broader patient population, and long-term data on the combination of these two compounds is limited.
This new schizophrenia medication offers a potentially new approach to treating schizophrenia, addressing symptoms without the typical side effects of current treatments. However, questions remain about its full range of effects, particularly on cognitive symptoms, and the long-term tolerability and safety of the treatment. The FDA’s decision, expected by September 2024, will determine if this drug can fulfil its promise as a significant advancement in schizophrenia treatment.
We Would Like to Hear Your Opinion
Join our Panel and be part of the M3 Global Research Community
More Resources for Healthcare Providers
Workplace Relationships in Healthcare: How to Build, Keep, and Repair Them
Poor workplace relationships in healthcare can harm mental health, job satisfaction, and patient care. Here’s how to build, maintain, and repair professional relationships among healthcare professionals.
How to Reduce Loneliness? 48% of Healthcare Providers Feel Lonely
A recent survey found that 48% of healthcare providers, especially physicians, feel lonely. Here are three tips to combat loneliness in healthcare.
latest posts
Peptide Technology Could Enable Oral Insulin Pills for Diabetes
*Molecular Pharmaceutics* study highlights Peptide technology enabling Oral insulin pills, offering an alternative to injections.
Study Reveals How Inflammation Drives Bone Loss in Aggressive Childhood Leukaemia
Blood Journal study shows inflammation drives bone loss in childhood leukaemia, including aggressive lymphoblastic leukaemia.
Moral Injury in Medicine: When Doing Your Best Still Feels Wrong
Moral injury in healthcare highlights deeper ethical conflict beyond burnout, with serious clinician wellbeing risks.
Join Today
Panel Members